316 related articles for article (PubMed ID: 19090674)
1. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
2. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
3. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
4. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
[TBL] [Abstract][Full Text] [Related]
6. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
7. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
8. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
9. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
10. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.
Van Laethem K; Schrooten Y; Covens K; Dekeersmaeker N; De Munter P; Van Wijngaerden E; Van Ranst M; Vandamme AM
J Virol Methods; 2008 Nov; 153(2):176-81. PubMed ID: 18706932
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
12. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
13. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
14. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
15. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
17. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
18. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
19. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
20. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
